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INTRODUCTION
Kawasaki disease (KD) is an acute febrile, multisystemic vas-
culitis syndrome, occurring mainly in children younger than 5 
years of age. It leads to inflammation that affects the small or 
medium-sized arteries, and this mechanism has clinical man-
ifestations.1 The most serious complications that can occur in 
KD are aneurysms or ectasia of the coronary artery and myo-
cardial infarction that can develop due to invasion of the coro-
nary artery.2 
The standard treatment in the acute phase of KD includes 
high-dose intravenous immunoglobulin (IVIG) and aspirin.3 
The mechanism of IVIG action is still under investigation; how-
ever, IVIG appears to have a generalized anti-inflammatory ef-
fect involving the inhibition of the interaction between cyto-
kines and endothelial cells. IVIG administration is known to 
reduce the incidence of coronary artery disease from 20−25% 
to 2−4%.4 However, 10−15% of patients with KD show persistent 
fever despite the administration of initial standard treatments. 
These patients are considered to be resistant to high-dose IVIG 
therapy, which in turn increases the risk of coronary artery le-
sions (CALs) and necessitates more aggressive treatment.5 
The standard treatment protocol for IVIG-resistant KD has 
not yet been decided. Corticosteroids are the second most 
commonly used medications to treat patients with KD who 
have a recurrent or persistent fever after IVIG treatment.6 Ad-
ditional second-line drugs for IVIG-resistant KD including 
methylprednisolone, infliximab, cyclosporine, cyclophospha-
mide, and methotrexate (MTX) have been reported. However, 
no standard medication has been established.3 
In 2002, we first reported a patient who was successfully 
treated for IVIG-resistant KD with MTX.7 In 2005, MTX was 
found to be efficacious in four additional patients who were 
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treated for IVIG-resistant KD.8 In 2008, we reported the use of 
MTX in 17 patients with a 5-year history of IVIG-resistant KD.9 
Previous studies have shown that MTX is effective in treating 
IVIG-resistant KD, has no adverse effects, and has economic 
advantages. By analyzing the data for 10 years, we evaluated 
the effectiveness of IVIG-resistant KD as a secondary drug and 
consolidating its position.
MTX is the second most commonly used drug for rheuma-
toid arthritis. As an inhibitor of dihydrofolate reductase, it is 
thought to play an anti-inflammatory role in the inflammatory 
responses of blood vessels in IVIG-resistant KD.9 In this study, 
we analyzed the clinical results of the administration of MTX 
as a therapeutic agent in patients with fever relapse or persis-
tent fever for 10 years.
 
MATERIALS AND METHODS
Study subjects
We retrospectively studied the electronic medical records of 
80 children admitted to Severance Children’s Hospital from 
July 2005 to November 2015. All the patients had fever for at 
least 5 days and fulfilled five of the six American Heart Associ-
ation (AHA) criteria for diagnosing KD (bilateral conjunctivitis; 
nonexudative mucosal change; erythema, peeling of the lips 
and strawberry tongue; cervical lymphadenopathy; single node 
>1.5 cm in diameter or several smaller, firm, polymorphous 
rashes, commonly maculopapular, which may involve early 
desquamation in the perineal region as well; erythema and 
induration of the hands or feet or both). All patients were ini-
tially administered high-dose IVIG (2 g/kg) and aspirin (100 
mg/kg) within the first 10 days of fever onset. The patients were 
considered IVIG-resistant when the fever (37.5°C, axillary tem-
perature) persisted or recurred 48 h after treatment with high-
dose IVIG and aspirin. Among the 80 patients, five were ex-
cluded because their final diagnoses were systemic juvenile 
rheumatic arthritis, Kikuchi disease, hemophagocytic lympho-
histiocytosis, gram-negative sepsis, and reactive arthritis. Fi-
nally, 75 cases were included in this study.
This study was approved by the Institutional Review Board 
of Severance Hospital, Seoul, Korea.
MTX treatment
Patients with persistent fever despite an initial treatment with 
IVIG received repeat IVIG and IV dexamethasone (0.3 mg/kg 
for 2−3 days) at the same dose. Nonetheless, 75 patients con-
tinued to have fever. We repeated the administration of IVIG, 
steroids, and additional MTX [10 mg/body surface area (BSA)] 
orally once a week, which is equivalent to the therapeutic dose 
for juvenile rheumatoid arthritis. The administration of MTX 
was continued in all patients until the fever subsided and clini-
cal symptoms were relieved. The steroid used at that time was 
discontinued for 2 to 3 days without tapering out. Day 1 was de-
fined as the first day of MTX administration, and laboratory 
tests were performed in all patients before and 1 week after treat-
ment. The response to treatment was determined to be non-re-
currence of the initial clinical symptoms within 7 days and res-
olution of fever (axillary temperature <37.5°C). The laboratory 
tests conducted were determination of white blood cell count, 
hemoglobin, hematocrit, platelet count, aspartate aminotrans-
ferase, albumin, erythrocyte sedimentation rate (ESR), and C-
reactive protein (CRP). Echocardiography was performed for 
each patient on admission and within 1 week of hospitalization 
and after the fever was absent.
Statistical analysis
The statistical analyses were conducted using the statistical 
package for the social sciences (SPSS) software, version 20.0 
(IBM Corp., Armonk, NY, USA). Statistical analysis was per-
formed using Wilcoxon matched pairs signed rank test. The 
categorical data were assessed using the chi-squared test. All 
p-values <0.05 were considered statistically significant. An in-
dependent sample t-test was used to compare the results of two 
groups with and without CALs. 
15
10
5
0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Year
Age: 36.6 months (5–110)
Gender M:F=1.8:1
Nu
m
be
r o
f M
TX
 tr
ea
tm
en
t
Fig. 1. Annual distribution of methotrexate (MTX) treatment for intravenous immunoglobulin resistant Kawasaki disease.
115
Hyejin Jang, et al.
https://doi.org/10.3349/ymj.2018.59.1.113
RESULTS
Subjects characteristics
MTX was prescribed to 3 to 12 patients with IVIG-resistant KD 
annually for 10 years between 2005 and 2015 (Fig. 1). The pa-
tient age at disease onset ranged from 5 months to 9.2 years 
(median, 36. 6 months). The sex distribution showed 1.8 times 
higher proportion of boys than girls (Table 1).
MTX treatment 
The median value of the maximum body temperature de-
creased significantly within 24 hours of MTX treatment (37.8 
vs. 37.1°C, p<0.001) (Fig. 2). The patients’ body temperatures 
remained well below fever levels even 2 and 3 days (37.0 and 
36.9°C, respectively) after MTX administration. The mean CRP 
level was significantly lowered from 40.5 mg/L to 17.2 mg/L as 
shown in the laboratory tests performed 1 week after the first 
dose of MTX (Fig. 3). In the laboratory tests, white blood cell 
counts, hemoglobin, and ESR levels were slightly improved, 
but this was not statistically significant (Table 2). There were 
no serious KD-related complications, such as hypertension or 
thrombosis, among the patients who participated in this study. 
In addition, none of the patients administered MTX experi-
enced side effects, such as stomach and intestinal bleeding, 
blood and bone marrow problems, or liver dysfunction.
Concomitant steroid use
In patients with recurrent or persistent fever after the initial 
IVIG treatment, a steroid [dexamethasone (0.3 mg/kg/day)] was 
administered with IVIG. Furthermore, when fever persisted, 
dexamethasone (0.3 mg/kg/day) was co-administered with 
MTX for an average of 3.2 days. Steroids administered with 
MTX were used only once and discontinued without loss of 
dose, with or without fever. 
Table 1. Demographic and Laboratory Characteristics of the Patients 
Treated with MTX 
Characteristics n=75
Age (month)   36.6 (±23)
Male gender (%)      48 (64)
Weight (kg)      23 (±5.5)
WBC (×103/μL)     16.7 (±10.8)
Hb (g/dL)   10.2 (±1.1)
Hematocrit (%) 30.08 (±3.4)
Platelet count (×103/μL)     664 (±229)
CRP (mg/L)     40.5 (±39.7)
ESR (mm/hr)     81.6 (±32.3)
AST (IU/L)   42.28 (±63.9)
Duration of fever before initial IVIG (days)   5.97 (±1.5)
Total dose of IVIG (g/kg)   3.53 (±1.5)
MTX, methotrexate; WBC, white blood cell; Hb, hemoglobin; CRP, C-reactive 
protein; ESR, erythrocyte sedimentation rate; AST, aspartate aminotransfer-
ase; IVIG, intravenous immunoglobulin; SD, standard deviation.
Mean (±SD). 
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Fig. 2. Fever patterns of the patients with intravenous immunoglobulin 
resistant Kawasaki disease before and after MTX treatment. MTX, 
methotrexate.
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Fig. 3. Serum CRP level of the patients with intravenous immunoglobulin 
resistant Kawasaki disease before and 7 days after MTX treatment. CRP, 
C-reactive protein; MTX, methotrexate.
Coronary artery lesion
Echocardiography procedures were performed for all the pa-
tients with IVIG-resistant KD who were treated with MTX on 
admission and 1 week after treatment. Of the 75 patients en-
rolled in this study, 21 (28%) had CALs. Patients were classified 
based on coronary artery z-score classification according to 
the AHA criteria using the echocardiography results. Among 
the 75 patients treated with MTX, 7 and 6 patients had z-scores 
of 2.5−4.9 and 5.0−9.0, respectively, while 1 patient had a score 
of >9 points (Table 3). Twenty-one patients were classified ac-
cording to the position of their coronary arteries. Coronary ar-
tery complications were bilateral in eight cases, consisting of a 
right main coronary artery in two cases, left main coronary ar-
tery in 10 cases, and left anterior descending artery in one case 
(Table 3). 
Twenty-one patients with CAL were examined using echo-
cardiography procedures after 2−3 months. The coronary ar-
tery z-score ranged from 4.0 to 3.7 (p=0.076). The CALs did not 
progress, although the improvement was not statistically sig-
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nificant following MTX treatment. This result indicates that 
MTX treatment did not prevent the aggravation or regression 
of CAL. There were no statistically significant blood test re-
sults following MTX administration to 21 and 54 patients with 
and without CAL, respectively (Table 4).
DISCUSSION
Although the cause of KD is still unclear, it is speculated to be 
a hypersensitivity or abnormal immunological reaction in 
children with a genetic predisposition induced by offending 
agents, which may be an infection or inflammation.10 These 
processes occur in small- to medium-sized arteries, and gen-
eralized vasculitis occurs, invading the entire body and mani-
festing various clinical symptoms.11 Approximately 7−9 days 
after the onset of fever, an influx of neutrophils occurs in the 
endothelial cells, vascular media, and elastic lamina, followed 
by the proliferation of CD8+ (cytotoxic) lymphocytes and im-
munoglobulin A-producing plasma cells. 
Mast cells secrete various cytokines [tumor necrosis factor 
(TNF), vascular endothelial growth factor (VEGF), and mono-
cyte chemotactic and activating factor], interleukins (IL-1, IL-
4, and IL-6), and matrix metalloproteinases (MMP3 and MMP9) 
that target the endothelial cells and cause vascular damage.12,13 
In severely affected vessels, the media develops inflammation 
with necrosis of smooth muscle cells, and the internal and ex-
ternal elastic laminae can split, leading to aneurysms. Over 
the next few weeks to months, the active inflammatory cells 
are replaced by fibroblasts and monocytes, and fibrous con-
nective tissue begins to form within the vessel wall.14 The intima 
proliferates and thickens while the vessel wall eventually nar-
rows or occludes, owing to stenosis or a thrombus. Recent stud-
ies have shown that features, including KD susceptibility, se-
verity, immunopathogenesis, reactivity to IVIG treatment, and 
coronary artery complications, are associated with genetic 
susceptibility. It has been shown that innate immunity plays a 
more important role in immunopathogenesis of disease than 
acquired immunity, but there are still many areas to be studied.15
Initial treatment with IVIG (2 g/kg) and aspirin (100 mg·kg-1· 
day-1) reduces the incidence of coronary lesions in KD from 
20% to 4%, leading to the rapid onset of the normalization of 
systemic inflammatory markers.16 IVIG is known to have a 
generalized anti-inflammatory effect, and its possible mecha-
nism of action includes the regulation of cytokine production 
and neutralization of bacterial superantigen.17 
Even with standard treatment with IVIG and aspirin, approx-
imately 10−15% of patients with KD show persistent or recur-
rent fever (IVIG-resistant KD), which increases their risk for 
CAL.18 Several co-treatments have been reported to be used 
Table 2. Laboratory Data before and 7 Days after MTX Treatment for 
Patients with IVIG-Resistant KD
Lab Before After p value
WBC (×103/μL)   16.7 (±10.8)   14.6 (±11.6) 0.080
Hb (g/dL) 10.2 (±1.1) 10.0 (±1.2) 0.670
ESR (mm/hr)   81.6 (±32.3)   80.6 (±29.1) 0.765
CRP (mg/L)   40.5 (±39.7)   17.2 (±16.9) 0.002
MTX, methotrexate; IVIG, intravenous immunoglobulin; KD, Kawasaki dis-
ease; WBC, white blood cell; Hb, hemoglobin; ESR, erythrocyte sedimenta-
tion rate; CRP, C-reactive protein; SD, standard deviation.
Mean (±SD), independent t-test and chi-squared test, p<0.05. 
Table 3. Z-score and Position of Coronary Artery Lesion
No. patients
Z-score
<2.5   7
2.5−4.9   7
5.0−9.0   6
>9   1
Position
Bilateral   8
LCA main 10
LAD   1
RCA   2
LCA, left coronary artery; LAD, left anterior descending; RCA, right coronary 
artery.
Table 4. Comparison of Demographic Characteristics and Laboratory Findings between CALs (-) and (+) Groups
Characteristics CALs (-) (n=54 ) CALs (+) (n=21) p value
WBC count (×103/μL) 16.9 16.0 0.738
Hb (g/dL) 10.3 10.0 0.262
CRP (mg/L) 33.0 44.6 0.302
ESR (mm/hr) 80.7 87.0 0.452
Duration of fever before initial IVIG (days)     6.33     5.05 0.069
Total dose of IVIG (g/kg)     3.42     3.82 0.292
Duration of fever before starting MTX (days)     4.38     6.05 0.072
Cumulative dose of MTX (mg/BSA)     4.13     3.74 0.416
Total fever days 11.1 11.8 0.621
CALs, coronary artery lesions; WBC, white blood cell; Hb, hemoglobin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IVIG, intravenous immuno-
globulin; MTX, methotrexate; BSA, body surface area.
Mean, independent t-test and chi-squared test, p<0.05. 
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with repeated infusions of IVIG, including IV methylpredniso-
lone, infliximab, abciximab, ulinastatin, MTX, cyclosporine, 
cyclophosphamide, and plasma exchange.15,19 IV methylpred-
nisolone (30 mg/kg infused for 2 hours and 3 days) rapidly sup-
presses cytokine levels and subsequently decreases capillary 
permeability, with outcomes similar to those of patients treat-
ed with a second dose of IVIG.20,21 Infliximab (5 mg/kg, IV infu-
sion) binds to TNF-α and prevents its activation. Thereby, IL 
and proinflammatory cytokines are reduced, and the activity 
of neutrophils and eosinophils is inhibited.22 Abciximab, a 
platelet glycoprotein IIb/IIIa receptor inhibitor, is associated 
with the resolution of thrombi and vascular remodeling in 
adults with acute coronary syndromes.23 Cyclosporine A (CyA) 
inhibits the assembly and release of IL-2, a cytokine signaling 
molecule, and inhibits the activation of T lymphocytes.24 Cy-
closporine has not been associated with CAL, but has shown 
side effects, such as hyperkalemia, hypertension, hirsutism, 
tremor, and renal dysfunction.25
In 2002, we reported the successful treatment of a patient 
with IVIG-resistant KD with MTX, originally.7 A 6-year-old boy 
diagnosed with KD was administered IVIG four times; how-
ever, the fever persisted even with co-treatment with dexa-
methasone. On day 31 after the disease onset, MTX (10 mg/
BSA, PO once weekly) was initiated and successfully resolved 
the clinical symptoms. However, a massive bilateral coronary 
aneurysmal ectasia was confirmed 2 months later by echocar-
diography, suggesting that MTX did not affect the progression 
of CALs. In 2005, MTX was reported to be effective in an addi-
tional four cases of IVIG-resistant KD in patients with an age 
distribution ranging from 8 months to 8 years and 9 months.8 
IVIG was administered 2−3 times, and dexamethasone was 
used for several days over 3−12 days; however, the fever per-
sisted, and low-dose MTX was administered (PO). The fever 
was controlled in all four patients within 3 days, although there 
was no improvement of CAL with MTX in this study. In 2008, 
we reported the use of MTX in 17 patients with IVIG-resistant 
KD over 5 years. The age of the patients at the disease onset 
ranged from 4 months to 8 years (median, 2.7 years). All the pa-
tients were controlled successfully with MTX, which showed 
no adverse effects in this study. Furthermore, the number and 
size of CALs did not decrease, as shown by the echocardiogra-
phy procedure before and after MTX administration.
In this study, MTX (10 mg/m2 weekly PO) was used as a 
secondary agent for KD at the same low doses used in rheu-
matoid arthritis and appeared to interfere with the hypersen-
sitivity or abnormal immunological reaction.26 We have not 
elucidated the exact mechanism by which MTX shows efficacy 
in IVIG-resistant KD; however, the following mechanisms 
have been suggested. These include the inhibition of enzymes 
involved in purine metabolism, leading to the accumulation 
of adenosine, inhibition of T-cell activation and suppression 
of intercellular adhesion molecules by T-cells, and selective 
downregulation of B-cells.27,28 Another proposed mechanism 
of action of MTX is the inhibition of methyltransferase activity, 
causing the inactivation of enzyme activity related to immune 
system function. These mechanisms may have contributed to 
the rapid fever resolution and improvement of inflammatory 
markers experienced by these patients treated with MTX. These 
results suggest that MTX is a potential candidate drug for sec-
ond-line therapy of IVIG-resistant KD. The administration of 
MTX to children is challenging because of its various side ef-
fects. In addition, MTX is used as an anticancer drug and, thus, 
it may create a sense of discomfort for patients and caregivers. 
Nevertheless, none of the patients enrolled in this study showed 
the common side effects of MTX, such as leukopenia, hepato-
toxicity, and ulcerative stomatitis.29  
The most serious complication of KD is CAL, and we have 
considered this from two perspectives. First, in patients with 
CAL, MTX was used to confirm the improvement, but no sta-
tistically positive results were obtained. Second, we observed 
that MTX could not prevent the development, formation, or 
aggravation of the observed CAL, which was not resolved. Our 
study had a few limitations including the concomitant use of 
steroids, which makes it difficult to assess the effect of MTX 
alone. In the case of recurrence of fever after initial IVIG treat-
ment, MTX was administered to IVIG and steroid for an aver-
age of 3.2 days, and the steroid used at that time was discontin-
ued without tapering out. The steroids administered with MTX 
were discontinued after a single dose, and because MTX was 
administered weekly to treat fever and symptoms, we deter-
mined that MTX played an important role in IVIG-resistant KD. 
The use of steroids did not appear to improve symptoms be-
cause MTX was added when the fever subsided. In addition to 
the clinical improvement described above, MTX has been ad-
ministered for 10 years, confirming that no particular side ef-
fect is associated with its use and, thus, it is superior as a second-
line drug. In addition to steroids, we have used cyclosporine 
in patients with IVIG-resistant KD, although we did not con-
tinue to do so because of poor results in the control of fever or 
improvement in the test. Second, this was not a controlled 
study. We retrospectively analyzed the data of patients admin-
istered MTX obtained from an electronic medical record da-
tabase. Therefore, there was no control in the design of subject 
recruitment and study. Third, this study was conducted in a 
single center and, therefore, MTX therapy should further be 
assessed in a multicenter, placebo-controlled trial. 
In conclusion, MTX effectively treated IVIG-resistant KD, im-
proved the patients’ clinical symptoms, and reduced the acute 
phase reactants. However, MTX did not affect the improvement 
or prevention of CAL. Finally, MTX could be a candidate for 
standard treatment for IVIG-resistant KD.
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